[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

  • M Siebels
  • A Hegele
  • Z Varga
  • R Oberneder
  • C Doehn
  • Hans Heinzer
  • Gesellschaft Für Immun- Und Targeted Therapie E.V. Deutsche

Beteiligte Einrichtungen

Abstract

Since 2006 in Germany six different target drugs for therapy in metastatic renal cell cancer (mRCC) have been used. Comparative studies for the application with the same indication are absent, and the order of potential sequential therapy is up to now unclear. The aim of the study was to collect data on therapy decisions in Germany regarding mRCC in the age of "targeted therapy". At the same time the study addressed the central question of sequencing of the different therapy options. In addition, the data of this study were to be compared to a study already published in 2008.

Bibliografische Daten

OriginalspracheDeutsch
Aufsatznummer9
ISSN0340-2592
StatusVeröffentlicht - 2011
pubmed 21559917